Stephen P. Hunger, MD, Chief of the Division of Oncology at CHOP talks about the evolution and promise of CAR T-cell therapies in the treatment of refractory acute lymphoblastic leukemia (ALL), and opportunities to explore using the breakthrough therapy at earlier stages of the disease.
Read the full article.